Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 262

1.

Role of primary care physicians in intrathecal pain management: a narrative review of the literature.

McDowell GC 2nd, Winchell J.

Postgrad Med. 2018 May;130(4):411-419. doi: 10.1080/00325481.2018.1448207. Epub 2018 Mar 28. Review.

PMID:
29542370
2.

Potential Uses of Isolated Toxin Peptides in Neuropathic Pain Relief: A Literature Review.

Hamad MK, He K, Abdulrazeq HF, Mustafa AM, Luceri R, Kamal N, Ali M, Nakhla J, Herzallah MM, Mammis A.

World Neurosurg. 2018 May;113:333-347.e5. doi: 10.1016/j.wneu.2018.01.116. Epub 2018 Feb 6. Review.

PMID:
29421449
3.

Intrathecal Drug Delivery and Spinal Cord Stimulation for the Treatment of Cancer Pain.

Xing F, Yong RJ, Kaye AD, Urman RD.

Curr Pain Headache Rep. 2018 Feb 5;22(2):11. doi: 10.1007/s11916-018-0662-z. Review.

PMID:
29404792
4.

Neuraxial drug delivery for the management of cancer pain: cost, updates, and society guidelines.

Clarke CFM.

Curr Opin Anaesthesiol. 2017 Oct;30(5):593-597. doi: 10.1097/ACO.0000000000000497. Review.

PMID:
28731876
5.

Chemical Stability of Morphine, Ropivacaine, and Ziconotide in Combination for Intrathecal Analgesia.

Robert J, Sorrieul J, Rossignol E, Beaussart H, Kieffer H, Folliard C, Dupoiron D, Devys C.

Int J Pharm Compd. 2017 Jul-Aug;21(4):347-351.

PMID:
28719378
6.

Perioperative Management of a Patient With an Intrathecal Drug Delivery Device Infusing Ziconotide: A Case Report.

Patel S, Hafez O, Sexton WJ, Edwards DA.

A A Case Rep. 2017 Feb 15;8(4):78-80. doi: 10.1213/XAA.0000000000000432.

PMID:
28195861
7.

Ziconotide intrathecal delivery as treatment for secondary therapeutic failure of motor cortex stimulation after 6 years.

Voirin J, Darie I, Fischer D, Simon A, Rohmer-Heitz I, Proust F.

Neurochirurgie. 2016 Oct;62(5):284-288. doi: 10.1016/j.neuchi.2016.06.007. Epub 2016 Oct 20.

PMID:
27771111
8.

Use of Low Dose Ziconotide as First-Line Intrathecal Monotherapy.

Prusik J, Argoff C, Peng S, Pilitsis JG.

Neuromodulation. 2017 Jun;20(4):386-391. doi: 10.1111/ner.12486. Epub 2016 Aug 5.

PMID:
27492135
9.

Intracerebroventricular Pain Treatment with Analgesic Mixtures including Ziconotide for Intractable Pain.

Staquet H, Dupoiron D, Nader E, Menei P.

Pain Physician. 2016 Jul;19(6):E905-15.

10.

Ziconotide Monotherapy: A Systematic Review of Randomised Controlled Trials.

Brookes ME, Eldabe S, Batterham A.

Curr Neuropharmacol. 2017;15(2):217-231. Review.

11.

The Pharmacology of Spinal Opioids and Ziconotide for the Treatment of Non-Cancer Pain.

Pope JE, Deer TR, Amirdelfan K, McRoberts WP, Azeem N.

Curr Neuropharmacol. 2017;15(2):206-216. Review.

12.

Intrathecal Ziconotide: Dosing and Administration Strategies in Patients With Refractory Chronic Pain.

McDowell GC 2nd, Pope JE.

Neuromodulation. 2016 Jul;19(5):522-32. doi: 10.1111/ner.12392. Epub 2016 Feb 9. Review.

13.

Delivery of ziconotide to cerebrospinal fluid via intranasal pathway for the treatment of chronic pain.

Manda P, Kushwaha AS, Kundu S, Shivakumar HN, Jo SB, Murthy SN.

J Control Release. 2016 Feb 28;224:69-76. doi: 10.1016/j.jconrel.2015.12.044. Epub 2015 Dec 28.

14.

A New, High Yield, Rapid, and Cost-Effective Protocol to Deprotection of Cysteine-Rich Conopeptide, Omega-Conotoxin MVIIA.

Eisapoor SS, Jamili S, Shahbazzadeh D, Ghavam Mostafavi P, Pooshang Bagheri K.

Chem Biol Drug Des. 2016 May;87(5):687-93. doi: 10.1111/cbdd.12702. Epub 2016 Jan 13.

PMID:
26662374
15.

Bioactive Mimetics of Conotoxins and other Venom Peptides.

Duggan PJ, Tuck KL.

Toxins (Basel). 2015 Oct 16;7(10):4175-98. doi: 10.3390/toxins7104175. Review.

16.

Molecular basis of toxicity of N-type calcium channel inhibitor MVIIA.

Wang F, Yan Z, Liu Z, Wang S, Wu Q, Yu S, Ding J, Dai Q.

Neuropharmacology. 2016 Feb;101:137-45. doi: 10.1016/j.neuropharm.2015.08.047. Epub 2015 Sep 4.

PMID:
26344359
17.

Electrophysiological evidence for voltage-gated calcium channel 2 (Cav2) modulation of mechano- and thermosensitive spinal neuronal responses in a rat model of osteoarthritis.

Rahman W, Patel R, Dickenson AH.

Neuroscience. 2015 Oct 1;305:76-85. doi: 10.1016/j.neuroscience.2015.07.073. Epub 2015 Aug 4.

18.

Tailored delivery of analgesic ziconotide across a blood brain barrier model using viral nanocontainers.

Anand P, O'Neil A, Lin E, Douglas T, Holford M.

Sci Rep. 2015 Aug 3;5:12497. doi: 10.1038/srep12497.

19.

Rationale for Prospective Assays of Intrathecal Mixtures Including Morphine, Ropivacaine and Ziconotide: Prevention of Adverse Events and Feasibility in Clinical Practice.

Dupoiron D, Devys C, Bazin C, Folliard C, Lebrec N, Boré F, Dubois PY, Kieffer H.

Pain Physician. 2015 Jul-Aug;18(4):349-57.

20.

Influence of pH and temperature on ziconotide stability in intrathecal analgesic admixtures in implantable pumps and syringes.

Bazin C, Poirier AL, Dupoiron D.

Int J Pharm. 2015 Jun 20;487(1-2):285-91. doi: 10.1016/j.ijpharm.2015.04.041. Epub 2015 Apr 16.

PMID:
25891257

Supplemental Content

Loading ...
Support Center